Free Trial

SpringWorks Therapeutics (SWTX) Stock Price, News & Analysis

SpringWorks Therapeutics logo
$46.99 0.00 (0.00%)
As of 07/1/2025

About SpringWorks Therapeutics Stock (NASDAQ:SWTX)

Key Stats

Today's Range
$46.99
$46.99
50-Day Range
$46.08
$46.99
52-Week Range
$28.21
$62.00
Volume
N/A
Average Volume
2.59 million shs
Market Capitalization
$3.54 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$52.57
Consensus Rating
Hold

Company Overview

SpringWorks Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
33rd Percentile Overall Score

SWTX MarketRank™: 

SpringWorks Therapeutics scored higher than 33% of companies evaluated by MarketBeat, and ranked 760th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    SpringWorks Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on 1 buy rating, 7 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    SpringWorks Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about SpringWorks Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for SpringWorks Therapeutics are expected to grow in the coming year, from ($2.05) to ($0.13) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of SpringWorks Therapeutics is -13.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of SpringWorks Therapeutics is -13.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    SpringWorks Therapeutics has a P/B Ratio of 7.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about SpringWorks Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    9.19% of the float of SpringWorks Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    SpringWorks Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in SpringWorks Therapeutics has recently increased by 2.24%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    SpringWorks Therapeutics does not currently pay a dividend.

  • Dividend Growth

    SpringWorks Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.19% of the float of SpringWorks Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    SpringWorks Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in SpringWorks Therapeutics has recently increased by 2.24%, indicating that investor sentiment is decreasing.
  • News Sentiment

    SpringWorks Therapeutics has a news sentiment score of 1.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for SpringWorks Therapeutics this week, compared to 7 articles on an average week.
Receive SWTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SpringWorks Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SWTX Stock News Headlines

$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
See More Headlines

SWTX Stock Analysis - Frequently Asked Questions

SpringWorks Therapeutics' stock was trading at $36.13 at the beginning of 2025. Since then, SWTX stock has increased by 30.1% and is now trading at $46.99.

SpringWorks Therapeutics (NASDAQ:SWTX) released its quarterly earnings results on Friday, May, 9th. The company reported ($1.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.81) by $0.30. The business earned $49.09 million during the quarter, compared to analyst estimates of $64.19 million. SpringWorks Therapeutics had a negative trailing twelve-month return on equity of 51.10% and a negative net margin of 115.60%.

SpringWorks Therapeutics subsidiaries include these companies: SpringWorks Subsidiary 1 Inc, SpringWorks Subsidiary 2 Inc, SpringWorks Subsidiary 3 Inc, SpringWorks Subsidiary 4 Inc, SpringWorks Therapeutics LLC, and SpringWorks Therapeutics Operating Company Inc..

SpringWorks Therapeutics (SWTX) raised $126 million in an initial public offering on Friday, September 13th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. ​J.P. Morgan, Goldman Sachs and Cowen​ ​ acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

SpringWorks Therapeutics' top institutional investors include Parallel Advisors LLC. Insiders that own company stock include Orbimed Advisors Llc, Saqib Islam, Badreddin Edris, Daniel Lynch, Bhavesh Ashar, Daniel Pichl and Julie Hambleton.
View institutional ownership trends
.

Shares of SWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that SpringWorks Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

Last Earnings
5/09/2025
Today
7/10/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SWTX
CIK
1773427
Fax
N/A
Employees
230
Year Founded
2017

Price Target and Rating

High Price Target
$68.00
Low Price Target
$47.00
Potential Upside/Downside
+11.9%
Consensus Rating
Hold
Rating Score (0-4)
2.13
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.41)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$258.13 million
Net Margins
-115.60%
Pretax Margin
-115.60%
Return on Equity
-51.10%
Return on Assets
-43.80%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.33
Quick Ratio
4.18

Sales & Book Value

Annual Sales
$191.59 million
Price / Sales
18.48
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.47 per share
Price / Book
7.26

Miscellaneous

Outstanding Shares
75,350,000
Free Float
69,449,000
Market Cap
$3.54 billion
Optionable
Optionable
Beta
0.68

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:SWTX) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners